0.8419 USD
-0.06 (-6.46%)
0.8486 USD
+0.01 (+0.8%)
We assign a fundamental rating of 3 out of 10 to ENSC. ENSC was compared to 529 industry peers in the Biotechnology industry. The financial health of ENSC is average, but there are quite some concerns on its profitability. ENSC has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- ENSC had negative earnings in the past year.
- ENSC had a negative operating cash flow in the past year.
- In the past 5 years ENSC reported 4 times negative net income.
- ENSC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- ENSC has a worse Return On Assets (-345.10%) than 92.23% of its industry peers.
- Looking at the Return On Equity, with a value of -911.79%, ENSC is doing worse than 78.79% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.1% | ||
| ROE | -911.79% | ||
| ROIC | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for ENSC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, ENSC has more shares outstanding
- ENSC has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for ENSC has been reduced compared to a year ago.
2.2 Solvency
- ENSC has an Altman-Z score of -69.14. This is a bad value and indicates that ENSC is not financially healthy and even has some risk of bankruptcy.
- ENSC has a Altman-Z score of -69.14. This is amonst the worse of the industry: ENSC underperforms 92.61% of its industry peers.
- There is no outstanding debt for ENSC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -69.14 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- A Current Ratio of 1.27 indicates that ENSC should not have too much problems paying its short term obligations.
- The Current ratio of ENSC (1.27) is worse than 83.52% of its industry peers.
- ENSC has a Quick Ratio of 1.27. This is a normal value and indicates that ENSC is financially healthy and should not expect problems in meeting its short term obligations.
- ENSC has a worse Quick ratio (1.27) than 82.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
- ENSC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.48%, which is quite impressive.
- Looking at the last year, ENSC shows a small growth in Revenue. The Revenue has grown by 1.51% in the last year.
- ENSC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.86% yearly.
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%
3.2 Future
- The Earnings Per Share is expected to grow by 41.95% on average over the next years. This is a very strong growth
- ENSC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 176.07% yearly.
EPS Next Y64.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-55.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ENSC. In the last year negative earnings were reported.
- The Price/Forward Earnings ratio is 4.23, which indicates a rather cheap valuation of ENSC.
- Based on the Price/Forward Earnings ratio, ENSC is valued cheaper than 99.43% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of ENSC to the average of the S&P500 Index (24.26), we can say ENSC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.23 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as ENSC's earnings are expected to grow with 41.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.95%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- ENSC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
0.8419
-0.06 (-6.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-09 2026-03-09/amc
Inst Owners7.48%
Inst Owner Change0%
Ins Owners0.29%
Ins Owner Change0%
Market Cap2.98M
Revenue(TTM)4.49M
Net Income(TTM)-10.97M
Analysts82.86
Price Target25.73 (2956.18%)
Short Float %6.55%
Short Ratio1.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.92%
Min EPS beat(2)-46.21%
Max EPS beat(2)34.36%
EPS beat(4)2
Avg EPS beat(4)9.75%
Min EPS beat(4)-46.21%
Max EPS beat(4)54.8%
EPS beat(8)5
Avg EPS beat(8)24.08%
EPS beat(12)9
Avg EPS beat(12)31.22%
EPS beat(16)11
Avg EPS beat(16)-101.82%
Revenue beat(2)1
Avg Revenue beat(2)37.92%
Min Revenue beat(2)-30.95%
Max Revenue beat(2)106.79%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.81%
PT rev (3m)-3.81%
EPS NQ rev (1m)-34.76%
EPS NQ rev (3m)-86.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.5%
Revenue NQ rev (1m)100%
Revenue NQ rev (3m)-28.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 4.23 | ||
| P/S | 0.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.48 | ||
| P/tB | 2.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.37
EYN/A
EPS(NY)0.2
Fwd EY23.63%
FCF(TTM)-2.02
FCFYN/A
OCF(TTM)-1.99
OCFYN/A
SpS1.27
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -345.1% | ||
| ROE | -911.79% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-319.99%
ROA(5y)-221.77%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.27 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | -69.14 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-222.86%
EPS Next Y64.03%
EPS Next 2Y41.95%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.51%
Revenue growth 3Y13.86%
Revenue growth 5YN/A
Sales Q2Q%-85.58%
Revenue Next Year-55.42%
Revenue Next 2Y-41.42%
Revenue Next 3Y176.07%
Revenue Next 5YN/A
EBIT growth 1Y-74.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-209.36%
EBIT Next 3Y51.15%
EBIT Next 5YN/A
FCF growth 1Y41.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.63%
OCF growth 3YN/A
OCF growth 5YN/A
ENSYSCE BIOSCIENCES INC / ENSC FAQ
Can you provide the ChartMill fundamental rating for ENSYSCE BIOSCIENCES INC?
ChartMill assigns a fundamental rating of 3 / 10 to ENSC.
What is the valuation status for ENSC stock?
ChartMill assigns a valuation rating of 4 / 10 to ENSYSCE BIOSCIENCES INC (ENSC). This can be considered as Fairly Valued.
Can you provide the profitability details for ENSYSCE BIOSCIENCES INC?
ENSYSCE BIOSCIENCES INC (ENSC) has a profitability rating of 0 / 10.
How financially healthy is ENSYSCE BIOSCIENCES INC?
The financial health rating of ENSYSCE BIOSCIENCES INC (ENSC) is 5 / 10.